BOT Insider Trading

Insider Ownership Percentage: 20.83%
Insider Buying (Last 12 Months): A$17,685.31
Insider Selling (Last 12 Months): A$0.00

Botanix Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Botanix Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Botanix Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for BOT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Botanix Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/20/2023H. William BoschInsiderExercise500,000A$0.10A$48,500.00
1/3/2023H. William BoschInsiderIssued1,500,000A$0.05A$78,000.00
12/12/2022Stewart WasherInsiderIssued5,000,000A$0.06A$290,000.00
7/7/2022H. William BoschInsiderBuy321,551A$0.06A$17,685.31
3/22/2022Daniel SharpInsiderIssued5,000,000A$0.07A$355,000.00
2/21/2022Stewart WasherInsiderExpiry4,000,000A$0.06A$232,000.00
6/30/2020Stewart WasherInsiderIssued4,863,490A$0.04A$189,676.11
5/8/2020Michael ThurnInsiderExpiry2,882,837A$0.05A$129,727.67
See Full Table

SEC Filings (Institutional Ownership Changes) for Botanix Pharmaceuticals (ASX:BOT)

5.98% of Botanix Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Botanix Pharmaceuticals logo
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.
Read More on Botanix Pharmaceuticals

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


1,627,221 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Botanix Pharmaceuticals?

Botanix Pharmaceuticals' top insider investors include:
  1. Daniel Sharp (Insider)
  2. H William Bosch (Insider)
  3. Stewart Washer (Insider)
Learn More about top insider investors at Botanix Pharmaceuticals.